Response to a Novel Multitargeted Tyrosine Kinase Inhibitor Pazopanib in Metastatic Merkel Cell Carcinoma
Matthew S. Davids(Harvard University), Boon Cher Goh(National University of Singapore), Mei Ling Chong(National University of Singapore), Richie Soong(National University of Singapore), Jeffrey P. Hodge(Research Triangle Park Foundation), Swee-Siang Ng(National University Health System), Amanda Charlton(The University of Sydney), Mohammed M. Dar(Queen's University Belfast), Kevin Laubscher(Research Triangle Park Foundation)
Cited by 81
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595